A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions; Biomarker
- Sponsors Yakult Honsha
- 08 Aug 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2016 Planned End Date changed from 30 Sep 2016 to 30 Sep 2017.